Diosmetin and its glycoside, diosmin, improve atopic dermatitis in DNCB‐induced hairless mice.

Naturally derived diosmetin and its glycoside diosmin are known to be effective in treating inflammatory disease. The aim of this study was to investigate the anti‐atopic dermatitis effect on diosmetin and diosmin 2,4‐dinitrochlorobenzen (DNCB)‐induced atopic dermatitis (AD) models. Oral administration of diometin or diosmin inhibited the development of DNCB‐induced AD‐like lesions in hairless mice by inhibiting transdermal moisture loss (TEWL) and improving skin hydration. Total serum immunoglobulin E (IgE) and interleukin‐4 (IL‐4) levels were also reduced in AD‐like lesion hairless mice skin samples treated with diosmetin or diosmin. In vitro , however, only diosmetin reduced the level of IL‐4 mRNA in RBL‐2H3 cells. Diosmin considered to be effective in the treatment of AD and skin inflammatory diseases by being converted into diosmetin in the body by pharmacokinetic metabolism. Thus oral administration of diosmetin and diosmin might be useful for the treatment of AD and cutaneous inflammatory diseases. Support or Funding Information This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF)& funded by the Korean government (MSIT) (Nos. NRF‐2019M3A9I3080263, NRF‐2019M3A9I3080265, and NRF‐2019M3A9I3080266).